THAR.Tharimmune, INC
10-Q: Tharimmune Inc. Reports Third Quarter 2024 Financial Results and Provides Business Update
Sentiment:
Quarterly Report
Tharimmune Inc. reported a net loss of $3.8 million for the third quarter of 2024, alongside updates on clinical trials and strategic agreements.
Capital raiseThe company has stated that it will need substantial additional funding to support future operating activities.The company may seek to raise additional funding through the sale of additional equity or debt securities, enter into strategic partnerships, grants, or other arrangements.The company recently closed a private placement offering (PIPE Offering) with certain accredited investors, consisting of an offering of shares of the company's common stock and/or pre-funded warrants to acquire shares of the company's common stock and warrants to acquire shares of the company's common stock, with net proceeds to the company of approximately $1.8 million.
Worse than expectedThe company's net loss increased significantly in Q3 2024 compared to Q3 2023.The company's cash reserves decreased significantly, raising concerns about its ability to fund future operations.The company's research and development expenses increased substantially, impacting the company's financials.
Summary
- Tharimmune Inc. reported a net loss of $3.8 million for the three months ended September 30, 2024, compared to a net loss of $1.8 million for the same period in 2023.
- The company's research and development expenses increased to $2.3 million for the quarter, up from $0.5 million in the prior year, primarily due to increased clinical trial and license fees.
- General and administrative expenses also rose to $1.6 million, a slight increase from $1.4 million in the same quarter of 2023.
- For the nine months ended September 30, 2024, the net loss was $8.4 million, compared to $6.8 million for the same period in 2023.
- The company's cash and cash equivalents totaled $4.8 million as of September 30, 2024, down from $10.9 million at the end of 2023.
- Tharimmune is developing therapeutic candidates in immunology and inflammation, including TH104 for chronic pruritis and TH023 for oral administration of infliximab.
- The company is also advancing a pipeline of novel therapeutic candidates targeting immuno-oncology targets such as HER2, HER3, and PD-1.
- The company has entered into a nonbinding letter of intent to acquire Intract Pharma Limited, a biopharmaceutical company developing oral biologics delivery solutions.
Sentiment
Score: 4
Explanation: The document presents a mixed picture. While there are positive developments in the pipeline and strategic moves, the significant increase in losses and decrease in cash reserves raise concerns about the company's financial stability and future prospects. The going concern warning further dampens the sentiment.
Positives
- Tharimmune is actively advancing its pipeline with multiple therapeutic candidates in development.
- The company has secured a license for an oral anti-TNF monoclonal antibody, expanding its portfolio.
- The proposed acquisition of Intract Pharma could create a synergistic oral biologics company.
- The company has a manufacturing agreement in place for clinical trial supply of TH104.
- Tharimmune is actively pursuing strategic collaborations and M&A opportunities to maximize pipeline value.
Negatives
- The company's net loss increased significantly in Q3 2024 compared to the same period in 2023.
- Research and development expenses have increased substantially, impacting the company's financials.
- Cash reserves have decreased significantly, raising concerns about the company's ability to fund future operations.
- The company has a history of operating losses and negative cash flows, raising substantial doubt about its ability to continue as a going concern.
Risks
- The company's ability to continue as a going concern is in doubt due to recurring losses and negative cash flows.
- Tharimmune needs to raise substantial additional capital to fund its operations and clinical trials.
- There is a risk that clinical trials may not be successful or may be delayed, impacting product development timelines.
- The company is dependent on third-party suppliers and manufacturers, which could pose risks to its supply chain.
- There is no guarantee that the company's products will be accepted in the marketplace or receive regulatory approvals.
- The company faces competition from other therapies and products that are or may become available.
Future Outlook
The company expects to obtain topline data in a Phase 2 trial with TH104 in Q4 2025 and intends to develop TH103 and potentially file an IND after discussion with regulators. The company also anticipates that TH0059 and TH1940 will progress to enter IND-enabling studies in 2025.
Management Comments
- The company believes the merger and business combination with Intract will form a best-in-class, transformative oral biologics company.
- The synergies between the company's clinical-stage assets and Intract's delivery platform will drive pipeline growth.
Industry Context
The company's focus on oral biologics and immuno-oncology aligns with current industry trends towards more convenient and targeted therapies. The acquisition of Intract Pharma is a strategic move to enhance its capabilities in oral drug delivery, a growing area of interest in the pharmaceutical industry.
Comparison to Industry Standards
- Tharimmune's increased R&D spending is typical for a clinical-stage biotech company, but the rate of increase is significant compared to peers.
- The company's cash burn rate is concerning, as many biotech companies with similar pipelines have more robust cash reserves.
- The proposed acquisition of Intract is a bold move, similar to other biotech companies acquiring technology platforms to enhance their drug delivery capabilities.
- The company's focus on bispecific antibodies and antibody-drug conjugates is in line with current trends in immuno-oncology, but the company is still in early stages compared to larger players like Regeneron or Genmab.
- The company's development of a PD-1 Picobody is a novel approach, but it is still in pre-clinical stages compared to companies with approved PD-1 inhibitors like Merck and Bristol-Myers Squibb.
Stakeholder Impact
- Shareholders may be concerned about the company's increasing losses and decreasing cash reserves.
- Employees may be affected by the company's financial instability and potential restructuring.
- Customers and suppliers may be impacted by the company's ability to continue operations and fulfill its obligations.
- Creditors may be concerned about the company's ability to repay its debts.
Next Steps
- The company will continue to develop TH104 and expects topline data from a Phase 2 trial in Q4 2025.
- The company will seek regulatory authorization to initiate a first-in-human bioavailability clinical trial for TH023.
- The company will advance pre-clinical candidate selection activities against HER2/HER3 receptors.
- The company will continue to develop TH1940, TH0059 and other multi-specific antibodies.
- The company will pursue strategic collaboration opportunities and potential M&A transactions.
- The company will work towards closing the acquisition of Intract Pharma.
Key Dates
| Date | Description |
|---|---|
| 2019-12-29 | Date of Asset Purchase Agreement for small molecule analogues. |
| 2021-05-30 | Date of Restated Employment Agreement. |
| 2022-01-14 | Date of initial public offering (IPO). |
| 2023-01-01 | Date of insurance premium financing agreement. |
| 2023-05-02 | Date of May public offering. |
| 2023-07-05 | Effective date of Research and Development Collaboration and License Agreement with Applied Biomedical Science Institute (ABSI). |
| 2023-07-26 | Date of common stock issuance to ABSI. |
| 2023-09-21 | Date of filing of Certificate of Amendment to change name to Tharimmune, Inc. |
| 2023-09-25 | Effective date of name change to Tharimmune, Inc. on Nasdaq. |
| 2023-11-03 | Effective date of Avior Patent License Agreement. |
| 2023-11-17 | Date of 1-for-25 reverse stock split. |
| 2023-11-30 | Date of November public offering. |
| 2024-01-23 | Date of corporate advisory consulting agreement. |
| 2024-03-11 | Date of addendum to ABSI Agreement. |
| 2024-05-14 | Date of amendment to the 2023 Omnibus Incentive Plan. |
| 2024-05-23 | Date of name change of HB Pharma Corp. to Hillstream Oncology, Inc. |
| 2024-05-24 | Date of 1-for-15 reverse stock split. |
| 2024-06-07 | Date of filing of Registration Statement on Form S-3 and ATM Agreement. |
| 2024-06-17 | Date of Enkefalos License Agreement and PIPE Offering. |
| 2024-07-25 | Date of manufacturing agreement for TH104 clinical trial supply. |
| 2024-09-11 | Date of Intract Patent License Agreement. |
| 2024-09-30 | Date of nonbinding letter of intent with Intract. |
| 2024-11-05 | Number of common shares outstanding as of this date. |
Keywords
Tharimmune, biotechnology, clinical trials, immuno-oncology, inflammation, HER2, HER3, PD-1, pruritis, infliximab, oral biologics, licensing, acquisition, INT-023, TH104, TH023, TH3215, TH1940, TH0059
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.